


REMARKS

Claims 1, 27-32, and 37-41 have been amended, claims 2-26 have been cancelled, and claims 50-56 have been added. Claim 1 has been amended for clarity, to recite "comprising" language, and to recite that the claimed peptide has at least one  $\alpha$ -helix stabilizing residue of Ac<sub>4</sub>c or Ac<sub>6</sub>c. Claims 27-32 have been amended for clarity and to recite "comprising" language. Claims 37-39 have been amended for clarity. Claim 40 has been amended to recite osteoporosis, and claim 41 has been amended to recite postmenopausal and old age osteoporosis. Support for these changes is found, for example, at page 8, line 30, to page 9, line 9. Support for new claims 51-55 is found, for example, in original claims 27-32. Support for new claim 56 is found, for example, at page 15, line 7. No new matter has been added by the present amendment.

If there are any additional charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 03 August 2009

  
Karen L. Elbing, Ph.D.  
Reg. No. 35,238

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045